CURRENT PRACTICE OF CLOPIDOGREL USE IN THE TREATMENT OF ACUTE CORONARY SYNDROME AT MILITARY HOSPITAL 175
Nội dung chính của bài viết
Tóm tắt
Objective: To analyze the current practice of Clopidogrel use in the treatment of acute coronary syndrome at Military Hospital 175.
Subjects and methods: A prospective cross-sectional descriptive study was conducted on 110 hospitalized patients diagnosed with acute coronary syndrome who received Clopidogrel therapy at the Department of Cardiology, Military Hospital 175, from January 2024 to November 2025.
Results: The study included 110 patients with acute coronary syndrome, predominantly male (77.3%), with a mean age of 65.2 ± 11.3 years. Dual antiplatelet therapy was predominantly used (96.4%), of which the combination of Aspirin and Clopidogrel accounted for the highest proportion (88.2%). The most commonly used loading-dose regimen was Aspirin 300 mg combined with Clopidogrel 300 mg (83.0%). The mean platelet aggregation after 6 days of maintenance-dose Clopidogrel was 42.0 ± 14.4%, with no significant difference between patients with ST-elevation myocardial infarction (42.6 ± 14.8%) and those with non-ST-elevation acute coronary syndrome (41.1 ± 13.9%) (p > 0.05). The overall rate of Clopidogrel resistance was 29.1%, which was comparable between the two clinical subgroups (p > 0.05).
Conclusion: Clopidogrel is widely used in the management of acute coronary syndrome at Military Hospital 175, primarily as part of dual antiplatelet therapy. The degree of platelet inhibition and the rate of Clopidogrel resistance did not differ significantly among clinical presentations of acute coronary syndrome.
Chi tiết bài viết
Từ khóa
Acute coronary syndrome, acute myocardial infarction, antiplatelet therapy.
Tài liệu tham khảo
[2] Beavers C.J, Patel P, Naqvi I.A. Clopidogrel. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025. https://pubmed.ncbi.nlm.nih.gov/29261873/
[3] Zocca P, Liefke C van der Heijden et al. Clopidogrel or Ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention, 2017, 13 (10): 1168-1176. doi: 10.4244/EIJ-D-17-00634.
[4] Pham Thuy Hang, Nguyen Thi Hanh, Luong Thanh Hoai Thu. Current use of antiplatelet therapy in the treatment of acute coronary syndrome at the Department of Cardiology, Kien An Hospital, Hai Phong, Vietnam, in 2017. Vietnam Medical Journal. 2022;515 (Special Issue, Part 1):105–112.
[5] Allami M. A cross-sectional study on the epidemiology and risk factors of acute coronary syndrome in Northern Iraq. Cureus, 2024, 16 (6): e63291. doi: 10.7759/cureus.63291.
[6] Al-Assadi M.Y, Aljaber N.N et al. Sex-related differences in acute coronary syndrome: insights from an observational study in a Yemeni cohort. Front Cardiovasc Med, 2025, 12: 1481917. doi: 10.3389/fcvm.2025.1481917.
[7] Pham Thi Ngoc Nga et al. Comprehensive analysis of demographic, clinical, and genetic characteristics in acute myocardial infarction patients. F1000Research, 2024. DOI: 10.12688/f1000research.154230.1
[8] He P, Luo X et al. Clinical outcome between Ticagrelor versus Clopidogrel in patients with acute coronary syndrome and diabetes. Cardiovascular Therapeutics, 2021: 5546260. doi: 10.1155/2021/5546260.
[9] Tran Song Giang et al. Early detection of resistance to dual antiplatelet therapy in patients who have undergone percutaneous coronary intervention using the VerifyNow test and associated factors. Medicine International, 2024, 4 (6): 56. doi: 10.3892/mi.2024.180.
[10] Ta Anh Hoang et al. Association of P2RY12 gene variants and non-genetic factors with Clopidogrel responsiveness in Vietnamese patients after percutaneous coronary intervention: A cross-sectional study. J Clin Lab Anal, 2025, 39 (5): e70003. doi: 10.1002/jcla.70003.